NIH launches pilot COVID telehealth program
Reuters
Published Jan 05, 2023 04:11PM ET
Updated Jan 05, 2023 06:10PM ET
(Reuters) - The U.S. National Institutes of Health (NIH) on Thursday launched a virtual program aimed at making antiviral treatments for COVID-19 available at home for those who test positive.
Local and state officials from Berks County in Pennsylvania will be the first to pilot the program, known as Home Test to Treat, later this month, with up to 8,000 residents expected to participate, the NIH said.
eMed, a privately-owned at-home health services firm, will host the official Home Test to Treat website, where individuals can sign up to receive antiviral treatment delivery as well as to coordinate telehealth-enabled test kits.
The public health agency has also engaged the UMass Chan Medical School in Worcester, Massachusetts, to collaborate with eMed on analyzing the data collected from the telehealth program such as the impact of a home-based process on testing and treatment.
The program, which was first announced in September by the White House, is aimed at increasing access for people in rural and high-risk communities.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.